Back to Search
Start Over
Statins use and its impact in EGFR-TKIs resistance to prolong the survival of lung cancer patients: A Cancer registry cohort study in Taiwan.
- Source :
-
Cancer science [Cancer Sci] 2020 Aug; Vol. 111 (8), pp. 2965-2973. Date of Electronic Publication: 2020 Jul 06. - Publication Year :
- 2020
-
Abstract
- Statins have been shown to be a beneficial treatment as chemotherapy and target therapy for lung cancer. This study aimed to investigate the effectiveness of statins in combination with epidermal growth factor receptor-tyrosine kinase inhibitor therapy for the resistance and mortality of lung cancer patients. A population-based cohort study was conducted using the Taiwan Cancer Registry database. From January 1, 2007, to December 31, 2012, in total 792 non-statins and 41 statins users who had undergone EGFR-TKIs treatment were included in this study. All patients were monitored until the event of death or when changed to another therapy. Kaplan-Meier estimators and Cox proportional hazards regression models were used to calculate overall survival. We found that the mortality was significantly lower in patients in the statins group compared with patients in the non-statins group (4-y cumulative mortality, 77.3%; 95% confidence interval (CI), 36.6%-81.4% vs. 85.5%; 95% CI, 78.5%-98%; P = .004). Statin use was associated with a reduced risk of death in patients the group who had tumor sizes <3 cm (hazard ratio [HR], 0.51, 95% CI, 0.29-0.89) and for patients in the group who had CCI scores <3 (HR, 0.6; 95% CI, 0.41-0.88; P = .009). In our study, statins were found to be associated with prolonged survival time in patients with lung cancer who were treated with EGFR-TKIs and played a synergistic anticancer role.<br /> (© 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.)
- Subjects :
- Aged
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Drug Resistance, Neoplasm drug effects
Drug Synergism
ErbB Receptors antagonists & inhibitors
Female
Follow-Up Studies
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use
Kaplan-Meier Estimate
Lung Neoplasms mortality
Male
Middle Aged
Protein Kinase Inhibitors therapeutic use
Registries statistics & numerical data
Retrospective Studies
Taiwan epidemiology
Treatment Outcome
Antineoplastic Combined Chemotherapy Protocols pharmacology
Hydroxymethylglutaryl-CoA Reductase Inhibitors pharmacology
Lung Neoplasms drug therapy
Protein Kinase Inhibitors pharmacology
Subjects
Details
- Language :
- English
- ISSN :
- 1349-7006
- Volume :
- 111
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Cancer science
- Publication Type :
- Academic Journal
- Accession number :
- 32441434
- Full Text :
- https://doi.org/10.1111/cas.14493